CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• Qiang YW, Barlogie B, Rudikoff S, et al. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone. 2008;42(4):669–680.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22(8):1485–1493.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL. Where we were, where we are, where we are going: progress in multiple myeloma. Am Soc Clin Oncol Educ Book. 2014;34:199–203.
   Google Scholar
• van de Donk NW, Sonneveld P. Diagnosis and risk stratification in multiple myeloma. Hematol Oncol Clin North Am. 2014;28(5):791–813.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448.
   PubMed Web of Science ®Google Scholar
• Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008–2016.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456–473.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Kamps S, Mutis T, et al. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2012;26(2):199–213.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Lokhorst HM. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother. 2013;14(12):1569–1573.
   PubMed Web of Science ®Google Scholar
• Drent E, Groen RW, Noort WA, et al. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica. 2016;101(5):616–625.
   PubMed Web of Science ®Google Scholar
• Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225–3236.
   PubMed Web of Science ®Google Scholar
• Quarona V, Ferri V, Chillemi A, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci. 2015;1335:10–22. Epub;%2014 Jul 21. DOI:10.1111/nyas.12485
   PubMed Web of Science ®Google Scholar
• Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88(3):841–886.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25(1):1–12.
   PubMed Web of Science ®Google Scholar
• Zocchi E, Franco L, Guida L, et al. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993;196(3):1459–1465.
   PubMed Web of Science ®Google Scholar
• Ramaschi G, Torti M, Festetics ET, et al. Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Blood. 1996;87(6):2308–2313.
   PubMed Web of Science ®Google Scholar
• Kotlikoff MI, Kannan MS, Solway J, et al. Methodologic advancements in the study of airway smooth muscle. J Allergy Clin Immunol. 2004;114(2 Suppl):S18–31.
   PubMedGoogle Scholar
• Crowell PD, Goldstein AS. Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer. Mol Cell Oncol. 2017;4(2):e1279723.
   PubMed Web of Science ®Google Scholar
• Horenstein AL, Sizzano F, Lusso R, et al. CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. Mol Med. 2009;15(3–4):76–84.
   PubMed Web of Science ®Google Scholar
• Song EK, Lee YR, Kim YR, et al. NAADP mediates insulin-stimulated glucose uptake and insulin sensitization by PPARgamma in adipocytes. Cell Rep. 2012;2(6):1607–1619.
   PubMed Web of Science ®Google Scholar
• Costa F, Toscani D, Chillemi A, et al. Expression of CD38 in myeloma bone niche: a rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget. 2017;8(34):56598–56611.
   PubMedGoogle Scholar
• van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016;127(6):681–695.
   PubMed Web of Science ®Google Scholar
• Smithson G, Zalevsky J, Korver W, et al. TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion. AAI Annu Meeting, Am Assoc Immunologists. 2017;198(1 Supplement):224.220.
   Google Scholar
• de Weers M, Tai YT, Van D V, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Casneuf T, Van VJ, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959–970.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039–2049.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Groen RW, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12):2802–2810.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, Lammerts van Bueren JJ, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015;100(2):263–268.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev. 2016;270(1):95–112.
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124(21):3474–3475.
   Web of Science ®Google Scholar
• Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol. 2016;197(3):807–813.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Frerichs KA, Nijhof IS, et al. Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab. Clin Cancer Res. 2017;23(24):7498–7511.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Fcgamma-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood. 2015;125(5):762–766.
   PubMed Web of Science ®Google Scholar
• Chillemi A, Quarona V, Zito A, et al. Generation and characterization of microvesicles after daratumumab interaction with myeloma cells. Blood. 2015;126(23):1849.
   Web of Science ®Google Scholar
• Chillemi A, Quarona V, Antonioli L, et al. Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche. Front Immunol. 2017;8:305.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
   PubMed Web of Science ®Google Scholar
• Adams H, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry (CyTOF) evaluation of relapsed/refractory multiple myeloma (MM) pts (pts) treated with daratumumab supports immune modulation as a novel mechanism of action. Blood. 2016;128(22):4521.
   Web of Science ®Google Scholar
• Vijayan D, Young A, Teng MWL, et al. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17(12):709–724.
   PubMed Web of Science ®Google Scholar
• Horenstein AL, Quarona V, Toscani D, et al. Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma. Mol Med. 2016;22:10.
   Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 9;387(10027):1551–1560.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37–44.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47.
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109–1114.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Casneuf T, Di Cara A, et al. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15122 [Epub ahead of print].
   PubMedGoogle Scholar
• de Haart SJ, Holthof L, Noort WA, et al. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica. 2016;101(8):e339–342.
   PubMed Web of Science ®Google Scholar
• Casneuf T, Xu XS, Adams HC, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1(23):2105–2114.
   PubMed Web of Science ®Google Scholar
• van de Veer M, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2):284–290.
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2):284–290.
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1(10):e41.
   PubMed Web of Science ®Google Scholar
• Plesner T, Arkenau HT, Gimsing P, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016;128(14):1821–1828.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Casneuf T, Chiu C, et al. Evaluation of minimal residual sisease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone. Blood. 2016;128(22):246.
   Web of Science ®Google Scholar
• San Miguel JF, Dimopoulos M, Usmani S, et al. Depth of response and MRD with daratumumab plus lenalidomide and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in RRMM: POLLUX IMW, OP-028. Clin Lymphoma Myeloma Leuk. 2017;17:e17-e18.
   Google Scholar
• Usmani S, Dimopoulos M, Belch A, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of Pollux. Blood. 2016;128(22):1151.
   Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Weisel K, San-Miguel J, Cook G, et al. Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. J Clin Oncol. 2017;35(suppl):8006.
   Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066.
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–981.
   PubMed Web of Science ®Google Scholar
• Garcia-Guerrero E, Gogishvili T, Danhof S, et al. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood. 2017;129(25):3386–3388.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 Feb 8;378(6):518-528.
   Web of Science ®Google Scholar
• Bringhen S, Evangelista A, Offidani M, et al. A simple score, based on geriatric assessment, improves prediction of survival, and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients. Blood. 2013;122(21):687–688.
   Web of Science ®Google Scholar
• Jakubowiak A, Chari A, Lonial S, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol. 2017 May;35(Supp 15):8000. doi: 10.1200/JCO.2017.35.15_suppl.8000.
   Web of Science ®Google Scholar
• van de Donk NW, Mutis T, Poddighe PJ, et al. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol. 2016;38 Suppl 1(Suppl 1):110–122.
   PubMedGoogle Scholar
• Ghobrial IM, Landgren O. How I treat smoldering multiple myeloma. Blood. 2014;124(23):3380–3388.
   PubMed Web of Science ®Google Scholar
• Hofmeister CC, Chari A, Cohen Y, et al. Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study. Blood. 2017;130(130):abstract 510.
   Google Scholar
• Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin. Cancer Res. 2014;20(17):4574–4583.
   PubMed Web of Science ®Google Scholar
• Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2):399–408.
   PubMed Web of Science ®Google Scholar
• Martin TG, Richter J, Vij R, et al. A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma. Blood. 2015;126(23):509.
   Web of Science ®Google Scholar
• Richter J, Martin TG, Vij R, et al. Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2016;34(suppl):8005.
   Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129(25):3294–3303.
   PubMed Web of Science ®Google Scholar
• Richardson P, Mikhael J, Usmani S, et al. Preliminary results from a phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Blood. 2016;128(22):2123.
   Web of Science ®Google Scholar
• Martin TG, Mannis G, Chari A, et al. Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma. Blood. 2016;128(22):2111.
   PubMed Web of Science ®Google Scholar
• Raab M, Chatterjee M, Goldschmidt H, et al. A phase I/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma. Blood. 2016;128(22):1152.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Raab M, Goldschmidt H, et al. A phase I/IIa study of the CD38 antibody MOR202 in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma IMW, PS-110. Clin Lymphoma Myeloma Leuk. 2017;17:e61.
   Web of Science ®Google Scholar
• McCudden CR, Voorhees PM, Hainsworth SA, et al. Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem. 2010;56(12):1897–1899.
   PubMed Web of Science ®Google Scholar
• McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54(6):1095–1104.
   PubMed Web of Science ®Google Scholar
• McCudden CR, Axel A, Slaets D, et al. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody. J Clin Oncol. 2015;33(Supp)8590.
   Web of Science ®Google Scholar
• van de Donk NW, Otten HG, El Haddad O, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med. 2016;54(6):1105–1109.
   PubMed Web of Science ®Google Scholar
• Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55(6 Pt 2):1555–1562.
   PubMed Web of Science ®Google Scholar
• Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545–1554.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Sonneveld P, Sun H. Daratumumab and blood-compatibility testing. N Engl J Med. 2016;375(25):2497–2498.
   PubMed Web of Science ®Google Scholar
• Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56(12):2964–2972.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896–905.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52–iv61.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Lokhorst HM, Dimopoulos M, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011;37(4):266–283.
   PubMed Web of Science ®Google Scholar
• Nijhof IS, van de Donk N, Zweegman S, et al. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018 Jan;78(1):19–37.
   Web of Science ®Google Scholar
• Chari A, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): PAVO, an open-label, multicenter, dose escalation phase 1b study. Blood. 2017;130(130):abstract 838.
   Google Scholar
• Alici E, Chrobok M, Lund J, et al. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. Br J Haematol. 2016;174(3):473–477.
   PubMed Web of Science ®Google Scholar
• Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, et al. The addition of IMiDs on daratumumab refractory multiple myeloma patients can overcome refractoriness in both agents. Blood. 2018 Jan 25;131(4):464–467.
   Web of Science ®Google Scholar
• Malavasi F, Deaglio S, Damle R, et al. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011;118(13):3470–3478.
   PubMed Web of Science ®Google Scholar